Background: Migraines affect 28 million people in the United States. Surgical treatment for migraine headaches refractory to medical treatment has grown recently for patient with limited options. Utility scores are standardized tools offering validated means of measuring the health state preference of a health condition or disease state. The aim of this study was to prospectively determine the impact of the health state burden prior to surgical treatment, to characterize the quality of life for this patient population.
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Background: Onabotulinumtoxin A (BOTOX®) is an FDA-approved treatment for chronic migraine headaches that involves on-label, high-dose administration across 31 anatomic sites. Anatomically-specific peripheral nerve trigger sites have been identified that contribute to migraine headache pathogenesis and are amenable to both BOTOX® injection and surgical decompression. These sites do not always correlate with the on-label FDA-approved injection pattern, but represent a more targeted approach. The efficacy of targeted peripheral nerve trigger site BOTOX® injection as an independent long-term therapeutic option has not been investigated.
Methods:
A retrospective review was completed for 223 patients with migraine headaches. Sixty-six patients elected to proceed with diagnostic BOTOX® injections. Of these, 24 continued long-term therapeutic BOTOX® injections while 42 matriculated to surgery. Outcomes were tracked.
results: Therapeutic long-term targeted trigger site-directed BOTOX® injection resulted in significant improvement in migraine headache index (MHI) (53.5+/-83.0, p<0.006), headache days/month (9.2+/-12.7, p<0.0009) and migraine severity (2.6+/-2.5, p<0.00008) versus baseline. MHI improved from the initiation of diagnostic injections to the establishment of steady-state injections (p<0.002), and further improved over time (p<0.05, mean follow-up 615 days) with no desensitization observed. Decompressive surgery resulted in significant improvement in MHI (100.8+/-109.7, p<0.0000005), headache days/month (10.8+/-12.7, p<0.000002), migraine severity (3.0 +/-3.8, p<0.00001), and migraine duration in hours (16.8+/-21.6, p<0.0007). MHI improvement with surgery was better than long-term BOTOX® injections (p<0.05).
conclusions: Though inferior to surgical decompression, targeted peripheral nerve trigger site-directed BOTOX® injection is an effective primary therapy for migraine headache representing a possible alternative to non-directed BOTOX® injection with decreased dosage requirements and the potential for decreased cost.
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